Effect of immunoglobulin G on the hepatic microvascular inflammatory response during sepsis

Shock

Volumn 5, Issue 1, 1996, Pages 28-33

  McCuskey, Robert S ^a   Nishida, Jiro ^a   McDonnell, Deboragh ^a   Baker, Gregory L ^a   Urbaschek, Renate ^b   Urbaschek, Bernhard ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; LIPOPOLYSACCHARIDE;

ANIMAL; ARTICLE; BLOOD; CYTOLOGY; HUMAN; IMMUNOLOGY; KUPFFER CELL; LIVER; MALE; MICROCIRCULATION; PHAGOCYTOSIS; RAT; SEPSIS; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; SURVIVAL RATE; VASCULARIZATION; VASCULITIS;

ANIMALS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KUPFFER CELLS; LIPOPOLYSACCHARIDES; LIVER; MALE; MICROCIRCULATION; PHAGOCYTOSIS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS; SPECIES SPECIFICITY; SURVIVAL RATE; VASCULITIS;

EID: 0029681770     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199601000-00007     Document Type: Article

References (35)

1. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA: Sepsis syndrome: A valid clinical entity. Crit Care Med 17:389-393, 1989.
2. Tran DD, Groeneveld ABJ, Meulen Jvd, Nauta JJP, Schijndel RJMSv, Thijs LG: Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit. Crit Care Med 15:474-479, 1990.
3. McCuskey RS: Hepatic microvascular responses to endotoxemia and sepsis. Prog Appl Microcirc 19:76-84, 1993.
4. McCuskey RS, Urbaschek R, McCuskey PA, Urbaschek B : Hepatic microvascular responses to tumor necrosis factor. In Wisse E, Knook DL, Decker K (eds): Cells of the Hepatic Sinusoids, II. Leiden, The Netherlands: Kupffer Cell Foundation, 1989, pp 272-276.
5. McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B: Kupffer cell function in host defense. Rev Infect Dis 5:S616-S619, 1987.
6. Nishida J, Ekataksin W, McDonnell D, Urbaschek R, Urbaschek B, McCuskey RS: Ethanol exacerbates hepatic microvascular dysfunction, endotoxemia and lethality in septic mice. Shock 1:413-418, 1994.
7. Decker K: Biologically active products of stimulated liver macrophages. Eur J Biochem 192:245-361, 1990.
8. Giroir BP: Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade. Crit Care Med 21:780-789, 1993.
9. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457-469, 1991.
10. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, Ballabio A, Sguotti C: Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 126:236-240,1991.
11. Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, Lasance A: Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. Intensive Care Med 11:288-294, 1985.
12. Cometta A, Baumgartner J-D, Lee ML, Hanique G, Glauser M-P: Prophylactic intravenous administration of standard immune globulin as compared with core-Iipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234-240, 1992.
13. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, Coldewey R, Deicher H: Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 19:1104-1113, 1991.
14. Neely AN, Holder IA: Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice. Antimicrob Agents Chemother 36:643-646, 1992.
15. Chudwin DS: Prophylaxis and treatment of pneumococcal bacteremia by immune globulin intravenous in a mouse model. Clin Immunol Imtmmopathol 50:62-71, 1989.
16. Pilz G, Kaab S, Neeser G, Class I, Schweigart U, Brahler A, Bujdoso O, Neumann R, Werdan K: Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock: An observational study as a prerequisite for placebo-controlled clinical trials. Infection 19:216, 1991.
17. Weisman LE, Lorenzetti PM: High intravenous doses of human immune -globulin suppress neonatal group B streptococcal immunity in rats. J Pediatr 115:445-450, 1989.
18. Imbach P, Hassig A, Cottier H: Possibilities of immunoprophylaxis and immunolherapy in gut-derived infectious-toxic shock (GITS). In Cottier H, Kraft R (eds): Current Studies in Hematology and Blood Transfusion. Basel, Switzerland: S. Karger, 1992, pp 301-323.
19. Emerson TE, Lurton JM, Collins MS: Efficaciousness of immunoglobulin G prophylaxis on mortality and physiological variables in Gram-negative peritonitis in rodents. Circ Shock 17:213-222, 1985.
20. Gardi A: Quality assurance, plasma sources and manufacture of intravenous immunoglobulin: The example of Sandoglobulin. In Kazatchkine MD (ed): Intravenous Immunoglobulin Therapy: Clinical Benefits and Future Prospects. London, UK: Parthenon Publishing Group, 1995, pp 109-114.
21. Schiff RI: Transmission of viral infections through intravenous immuno-globulins. New Engl J Med 331:1649-1650, 1994.
22. Iwata M, Shimozato T, Tokiwa H, Tsubura E: Antipyretic activity of a human immunoglobulin preparation for intravenous use in an experimental model of fever in rabbits. Infect Immun 55:547-554, 1987.
23. Shimozato T, Iwata M, Tamura N: Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 58:1384-1390, 1990.
24. Kremeier U, Ruiz-Morales M, Messmer K: Comparison of the effects of volume resuscitation with dextran 60 vs. Ringer's lactate on central hemodynamics, regional blood flow, pulmonary function and blood composition during hyperdynamic endotoxemia. Circ Shock 39:89-99, 1993.
25. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock: A review of laboratory models and a proposal. J Surg Res 29:189-201, 1980.
26. Urbaschek B, Becker KP, Ditter B, Urbaschek R: Quantification of endotoxin and sample-related interferences by using a kinetic limulus amebocyte lysate microtiter test. In Leive L (ed): Microbiology: 1985. Washington, DC: American Society of Microbiology, 1985, pp 39-43.
27. McCuskey RS: Microscopic methods for studying the microvasculature of internal organs. In Baker CH, Nastuk WF (eds): Physical Techniques in Biology and Medicine Microvascular Technology. New York: Academic Press, 1986, pp 247-264.
28. Glauser MP, Zanetti G, Baumgartner J-D, Cohen J: Septic shock: Pathogenesis. Lancet 338:732-736, 1991.
29. Cohen J: Intravenous immunoglobulin (IVIG) for Gram-negative infection: A critical review. J Hosp Infect 12:47-54, 1988.
30. Basta M, Kirshbom P, Frank MM, Fries LF: Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974-1981, 1989.
31. McCuskey RS, Nishida J, McDonnell D, Baker GL, Urbaschek R, Urbaschek B: Effect of immunoglobulin G (IgG) on Kupffer cell function, the hepatic microvascular response during sepsis. In Wisse E, Knook DL, Wake K (eds): Cells of the Hepatic Sinusoid V. Leiden, The Netherlands: Kupffer Cell Foundation, 1995, pp 21-24.
32. 57B1/6 mice. In Wisse E, Knook DL, McCuskey RS (eds): Cells of the Hepatic Sinusoid, III. Leiden, The Netherlands: Kupffer Cell Foundation, 1991,pp 465-468.
33. Bautista AP, Deaciuc IV, Jaeschke H, Spolarics Z, Spitzer JJ: Hepatic responses to bacterial endotoxin (LPS). In Schlag G, Redl H (eds): Pathophysiology of Shock, Sepsis and Organ Failure. Berlin: Springer-Verlag, 1993, pp 915-934.
34. Newland AC, Macey MC, Veys PA: Intravenous immunoglobulin: Mechanisms of action and their clinical application. In Imbach P (ed): Immunotherapy with Intravenous Immunoglobulins. San Diego: Academic Press, 1991, pp 15-25.
35. Decker, K: Hepatic mediators of inflammation in cells of the hepatic sinusoids. In Wisse E, Knook DL, Decker K (eds): Cells of the Hepatic Sinusoid. Rijswijk, The Netherlands: The Kupffer Cell Foundation, 1989, pp 171-175.